# NETTER-1 (NCT01578239)

> A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01578239
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Advanced Accelerator Applications
- Conditions: Carcinoid Tumor of the Small Bowel; Neuroendocrine Tumour
- Interventions: Octreotide LAR; 177Lu-DOTA0-Tyr3-Octreotate
- Enrollment: 231
- Primary outcome: Progression Free Survival (PFS)

## Commentary we found

- X threads: 36
- YouTube: 14
- Podcasts: 11

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=netter-1-nct01578239

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01578239", "email": "<work email>"}; the inbox owner confirms by the emailed link.